GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source
The Role of Incretins in Obstructive Sleep Apnea "GLP1RAs and GLP1RA/GIPRAs in OSA". [PDF]
Fuentes AL +4 more
europepmc +1 more source
Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey +7 more
wiley +1 more source
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)? [PDF]
Pack A +5 more
europepmc +1 more source
ABSTRACT Introduction Pregnancy concurrent with incretin‐based medications is contraindicated due to unknown risk of teratogenicity, as is breastfeeding. The aim of this systematic scoping review was to investigate potential risks and benefits of incretin‐based medications in relation to preconception, pregnancy, and postnatal health, and to propose ...
Kate Maslin +19 more
wiley +1 more source
Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Challenges and evidence in obesity guidelines. ABSTRACT Obesity remains a global health crisis characterized by substantial heterogeneity in diagnosis, management, and policy implementation. Although numerous national and international clinical practice guidelines have been published over the past decade, their translation into evidence‐based and ...
Rosero‐Revelo Ricardo +13 more
wiley +1 more source
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. [PDF]
Gupta M, Shukla J.
europepmc +1 more source
Beyond weight loss: Preserving muscle health in the incretin era
Journal of Diabetes Investigation, EarlyView.
Toshinori Imaizumi, Daisuke Yabe
wiley +1 more source
Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice. [PDF]
Kubota-Okamoto S +17 more
europepmc +1 more source
Selecting between pharmacotherapy and bariatric surgery in East Asia
Journal of Diabetes Investigation, EarlyView.
Yamato Keidai +4 more
wiley +1 more source

